Tests:Alpha Fetoprotein, Tumor Marker: Difference between revisions
Tests:Alpha Fetoprotein, Tumor Marker
No edit summary |
No edit summary |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 17: | Line 17: | ||
AFP (tumour marker) | AFP (tumour marker) | ||
|- | |- | ||
| | |Availability | ||
| | |Performed Mon-Fri. Available out of hours except weekends and public holidays | ||
|- | |- | ||
|Turnaround Time | |Turnaround Time | ||
| Line 24: | Line 24: | ||
|- | |- | ||
|Stability – Add test | |Stability – Add test | ||
| | |24 hours | ||
|- | |- | ||
! colspan="2" | | ! colspan="2" | | ||
== Specimen Requirements == | == Specimen Requirements == | ||
|- | |- | ||
|Specimen | |Specimen | ||
|Serum | |Serum | ||
|- | |- | ||
|Preferred | |Preferred | ||
| | |Plain Yellow-top or <span style="background:#e30022"> Red-Top </span> tube | ||
|- | |- | ||
|Acceptable | |Acceptable | ||
| | |Plain Yellow-top or <span style="background:#e30022"> Red-Top </span> tube | ||
|- | |- | ||
|Unacceptable | |Unacceptable | ||
| | |Plasma samples | ||
|- | |- | ||
|Paediatric Requirements | |Paediatric Requirements | ||
|0.5 mL <span style="background:# | |0.5 mL paediatric <span style="background:#e30022">Red-Top </span> | ||
|- | |- | ||
! colspan="2" | | ! colspan="2" | | ||
== Aliquot Requirements == | == Aliquot Requirements == | ||
|- | |- | ||
|Sample | |Sample | ||
|Serum | |Serum | ||
|- | |- | ||
| Line 68: | Line 67: | ||
|- | |- | ||
|Test Method | |Test Method | ||
| | |Abbott Alinity i series analyser using Abbott reagents. Chemiluminescent microparticle immunoassay. | ||
|- | |- | ||
|Advanced Notice | |Advanced Notice | ||
| Line 79: | Line 78: | ||
== Comments == | == Comments == | ||
|- | |- | ||
| colspan="2" | This test is useful as a tumour marker and as a safe and effective supplement to the management of patients undergoing treatment for non-seminomatous testicular cancer and | | colspan="2" | This test is useful as a tumour marker and as a safe and effective supplement to the management of patients undergoing treatment for non-seminomatous testicular cancer and | ||
certain germ cell cancers, or for patients being monitored after therapy is complete. | |||
The test is NOT a screening test for cancer. | |||
The test is NOT intended as a screen for neural tube defects. | The test is NOT intended as a screen for neural tube defects. | ||
| Line 87: | Line 87: | ||
For the serial monitoring of tumours, tumour markers should be tested in the same laboratory. | For the serial monitoring of tumours, tumour markers should be tested in the same laboratory. | ||
|} | |} | ||
{{DocMeta | |||
| owner = Crossley1 | |||
| review_ping = | |||
}} | |||
Latest revision as of 20:33, 23 September 2026
Overview | |
|---|---|
| Department | Biochemistry |
| Test Code | TAFP |
| Synonyms | Tumour Marker (AFP)
AFP (tumour marker) |
| Availability | Performed Mon-Fri. Available out of hours except weekends and public holidays |
| Turnaround Time | 1 hour to 3 days. |
| Stability – Add test | 24 hours |
Specimen Requirements | |
| Specimen | Serum |
| Preferred | Plain Yellow-top or Red-Top tube |
| Acceptable | Plain Yellow-top or Red-Top tube |
| Unacceptable | Plasma samples |
| Paediatric Requirements | 0.5 mL paediatric Red-Top |
Aliquot Requirements | |
| Sample | Serum |
| Preferred Volume | >500 µL |
| Minimum Volume | 200 µL |
| Aliquot Transportation | |
| == Clinical Information == | |
| Reference Intervals | 0 - 16 µg/L (non-pregnant)
See comment |
| Test Method | Abbott Alinity i series analyser using Abbott reagents. Chemiluminescent microparticle immunoassay. |
| Advanced Notice | Not required |
| Patient Preparation | Not required |
Comments | |
| This test is useful as a tumour marker and as a safe and effective supplement to the management of patients undergoing treatment for non-seminomatous testicular cancer and
certain germ cell cancers, or for patients being monitored after therapy is complete. The test is NOT a screening test for cancer. The test is NOT intended as a screen for neural tube defects. For the serial monitoring of tumours, tumour markers should be tested in the same laboratory. | |
| Owner | Clair Crossley (Crossley1) |
|---|---|
| Last reviewed | 23.09.2026 |
| Next review | 23.09.2027 (OK) |